Antibody against tumor necrosis factor-α reduces bortezomib-induced allodynia in a rat model

Anticancer Research

Volumn 33, Issue 12, 2013, Pages 5453-5459

  Chiorazzi, Alessia ^a   Canta, Annalisa ^a   Meregalli, Cristina ^a   Carozzi, Valentina ^a   Sala, Barbara ^a   Oggioni, Norberto ^a   Monbaliu, Johan ^b   Van De Velde, Helgi ^b   Cavaletti, Guido ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Allodynia; Anti TNF ; Bortezomib induced neuropathy; Tumor necrosis factor

Indexed keywords

ANALGESIC AGENT; BORTEZOMIB; CNTO 1081; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; MECHANICAL STIMULATION; NERVE CONDUCTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROPHYLAXIS; RAT; SYSTEMATIC REVIEW; THERMAL STIMULATION;

EID: 84891409384     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC: A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003.
2. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D and Anderson KC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498, 2005.
3. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, Stadtmauer EA, O'Connor OA, Shi H, Boral AL and Goy A: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24: 4867-4874, 2006.
4. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H and Richardson PG VISTA Trial Investigators: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359: 906-917, 2008.
5. Cavaletti G and Nobile-Orazio E: Bortezomib-induced peripheral neurotoxicity: Still far from a painless gain. Hematol J 92: 1308-1310, 2007.
6. Cavaletti G and Jakubowiak AJ: Peripheral neuropathy during bortezomib treatment of multiple myeloma: A review of recent study. Leuk Lymphoma 51: 1178-1187, 2010.
7. Dimopoulos MA, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H and San Miguel JF: Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalanprednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase III VISTA study. Eur J Haematol 86: 23-31, 2011.
8. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W and Harousseau JL: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase III, non-inferiority study. Lancet Oncol 12: 431-440, 2011.
9. Mateos MV and San Miguel JF: Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 3: 117-124, 2012.
10. Curran MP and McKeage K: Bortezomib. A review of its use in patients with multiple myeloma. Drugs 69: 859-888, 2009.
11. Chauhan D, Li G, Sattler M, Podar K, Mitsiades C, Mitsiades N, Munshi N, Hideshima T and Anderson KC: Superoxide-dependent mitochondrial signaling during apoptosis in multiple myeloma (MM) cells. Oncogene 22: 6296-6300, 2003.
12. Kropff M, Bisping G, Wenning D, Berdel WE and Kienast J: Proteasome inhibition in multiple myeloma. Eur J Cancer 42: 1623-1639, 2006.
13. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS and Anderson KC: Antimyeloma activity of heat-shock protein-90 inhibition. Blood 107: 1092-1100, 2006.
14. Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K and Yamana H: Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Ther 9: 1842-1851, 2010.
15. Mohammad AS, Maureen NB and Ali RJ: Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: Basic and clinical aspects. Am J Cancer Res 1: 913-924, 2011.
16. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, Ceresa C, Avezza F, Crippa L, Marmiroli P and Cavaletti G: Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats. Eur J Pain 14: 343-350, 2010.
17. Carozzi VA, Canta A, Oggioni N, Sala B, Chiorazzi A, Meregalli C, Bossi M, Marmiroli P and Cavaletti G: Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp Neurol 226: 301-309, 2010.
18. Meregalli C, Ceresa C, Canta A, Carozzi VA, Chiorazzi A, Sala B, Oggioni N, Lanza M, Letari O, Ferrari F, Avezza F, Marmiroli P, Caselli G and Cavaletti G: CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J Pain Res 5: 151-167, 2012.
19. Gilardini A, Avila RL, Oggioni N, Rodriguez-Menendez V, Bossi M, Canta A, Cavaletti G and Kirschner DA: Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy. Neurotoxicology 33: 1-7, 2012.
20. Eliyahu E, Wolfson T, Ge Y, Jepsen KJ, Schuchman EH and Simonaro CM: Anti-TNF-α therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. Plos ONE 6: 8, 2011.
21. Li J, Zhang H, Huang W, Qian H and Li Y: TNF-α inhibitors with anti oxidative stress activity from natural products. Curr Top Med Chem 12: 1408-1421, 2012.
22. Leung L and Cahill CM: TNF-α and neuropathic pain - a review. J of Neuroinflamm 7: 27-37, 2010.
23. Nadeau S, Filali M, Zhang J, Kerr BJ, Rivest S, Soulet D, Iwakura Y, de Rivero Vaccari JP, Keane RW and Lacroix S: Functional recovery after peripheral nerve injury is dependent on the pro-inflammatory cytokines IL-1β and TNF: Implications for neuropathic pain. J Neurosci 31: 12533-12542, 2011.
24. Stemkowski PL and Smith PA: Sensory neurons, ion channels, inflammation and the onset of neuropathic pain. Can J Neurol Sci 39: 416-435, 2012.
25. Sommer C, Schmidt C and George A: Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol 151: 138-142, 1998.
26. Wagner R, Myers RR and O'Brein JS: Prosaptide prevents hyperalgesia and reduces peripheral TNFR1 expression following TNFá nerve injection. NeuroReport 9: 2827-2831, 1998.
27. Sommer C and Kress M: Recent findings on how proinflammatory cytokines cause pain: Peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 361: 184-187, 2004.
28. Kolarz B, Targonska-Stepniak B, Darmochwal-Kolarz D and Majdan M: Autoimmune aspects of treatment with TNFα inhibitors. Postepy Hig Med Dosw 61: 478-484, 2007.
29. Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A, Galbiati S, Nicolini G, Scuteri A, Lanzani F, Giussani G and Cavaletti G: Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer 41: 1460-1466, 2005.
30. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, Marmiroli P, Bossi M, Oggioni N, D'Incalci M and De Coster R: Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat. Exp Neurol 204: 317-325, 2007.
31. Hargreaves K, Dubner R, Brown F, Flores C and Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88, 1988.
32. Little MA, Bhangal G, Smyth CL, Nakada MT, Cook HT, Nourshargh S and Pusey CD: Therapeutic effect of anti-TNFα antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 17: 160-169, 2006.
33. Milia AF, Ibba-Manneschi L, Manetti M, Benelli G, Generini S, Messerini L and Matucci-Cerinic M: Evidence for the prevention of enthesitis in HLA-B27/hβ(2)m transgenic rats treated with a monoclonal antibody against TNFα. J Cell Mol Med 15: 270-279, 2011.
34. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M and Palumbo A: Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116: 4745-4753, 2010.
35. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, Hentz J, Pirooz NA, Piza JG, Tiedemann R, Mikhael JR, Bergsagel PL, Leis JF, Fonseca R and Stewart AK: Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 115: 3416-3417, 2010.
36. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W and Harousseau JL: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase III, non-inferiority study. Lancet Oncol 12: 431-440, 2011.
37. Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, Varettoni M, Zappasodi P, Moglia A, Lazzarino M and Costa A: Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 119: 2507-2512, 2008.
38. Schmitt S, Goldschmidt H, Storch-Hagenlocher B, Pham M, Fingerle-Rowson G, Ho AD and Neben K: Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma. Int J Hematol 93: 791-794, 2011.
39. Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H and Sonneveld P: Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 11: 1057-1065, 2010.
40. Favis R, Sun Y, van de Velde H, Broderick E, Levey L, Meyers M, Mulligan G, Harousseau JL, Richardson PG and Ricci DS: Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 21: 121-129, 2001.
41. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D and Bidoli P: Chemotherapy-induced peripheral neurotoxicity assessment: A critical revision of the currently available tools. Eur J Cancer 46: 479-494, 2010.
42. Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, Ceracchi M, Ildebrando M and Cavaletti G: Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 16: 228-236, 2011.
43. Grisold W, Cavaletti G and Windebank AJ: Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 14 (Suppl 4): iv45-54, 2012.
44. Briani C, Torre CD, Campagnolo M, Lucchetta M, Berno T, Candiotto L, Padua L, Ermani M, Cavaletti G and Zambello R: Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: Results from a single-centre prospective study. J Peripher Nerv Syst 18: 19-24, 2013.
45. Wells MR, Racis SP Jr. and Vaidya U: Changes in plasma cytokines associated with peripheral nerve injury. J Neuroimmunol 39: 261-268, 1992.
46. Wang XM, Lehky TJ, Brell JM and Dorsey SG: Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 59: 3-9, 2012.
47. Drory VE, Lev D, Groozman GB, Gutmann M and Klausner JM: Neurotoxicity of isolated limb perfusion with tumor necrosis factor. J Neurol Sci 158: 1-4, 1998.
48. Casafont I, Berciano MT and Lafarga M: Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in SAM68 and PABPN1 in sensory ganglia neurons. Neurotox Res 17: 167-178, 2010.
49. George A, Schmidt C, Weishaupt A, Toyka KV and Sommer C: Serial determination of tumor necrosis factor-α content in rat sciatic nerve after chronic constriction injury. Exp Neurol 160: 124-132, 1999.
50. George A, Buehl A and Sommer C: Wallerian degeneration after crush injury of rat sciatic nerve increases endo- and epineurial tumor necrosis factor-α protein. Neurosci Lett 372: 215-219, 2004.
51. Shubayev VI and Myers RR: Up-regulation and interaction of TNFα and gelatinases A and B in painful peripheral nerve injury. Brain Res 855: 83-89, 2000.
52. Empl M, Renaud S, Erne B, Fuhr P, Straube A, Schaeren-Wiemers N and Steck AJ: TNFα expression in painful and nonpainful neuropathies. Neurology 56: 1371-1377, 2001.
53. Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, Kishida S, Kuniyoshi K, Nakamura J, Aoki Y, Ishikawa T, Arai G, Kamoda H, Suzuki M, Takaso M, Furuya T, Toyone T and Takahashi K: Epidural administration of spinal nerves with the tumor necrosis factor-α inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: A prospective randomized study. Spine 37: 439-444, 2012.
54. Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Järvinen S, Niinimäki J, Veeger N, Seitsalo S and Hurri H: The treatment of disc herniation-induced sciatica with infliximab: Results of a randomized, controlled, 3-month follow-up study. Spine 30: 2724-2728, 2005.
55. Korhonen T, Karppinen J, Paimela L, Malmivaara A, Lindgren KA, Bowman C, Hammond A, Kirkham B, Järvinen S, Niinimäki J, Veeger N, Haapea M, Torkki M, Tervonen O, Seitsalo S and Hurri H: The treatment of disc-herniation-induced sciatica with infliximab: One-year follow-up results of FIRST II, a randomized controlled trial. Spine 31: 2759-2766, 2006.
56. Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, Millard L, Rohatiner A, Boral A, Trehu E, Schenkein D, Balkwill F, Joel SP and Lister TA: Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor α response with clinical activity. J Clin Oncol 24: 2105-2112, 2006.
57. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C and Mutti L: Bortezomib inhibits nuclear factor-KB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 13: 5942-5951, 2007.